Maze Therapeutics reported positive mid-Stage data in its Phase 2 study of MZE829, a genetic kidney disease therapy that targets a mechanism intended to compete in the same target space as Vertex’s program. The company’s results support continued development and raise pressure on incumbents as genetic kidney disease treatments move deeper into comparative efficacy positioning.